And speaking of NASH, I noticed that RA Capital increased their already large position in 89Bio which has a P1 trial for a NASH treatment that will be weekly or biweekly SC dosed. Would a potential RNAi RX have much longer action?
RA Capital disclosed a larger position in the clinical-stage biopharmaceutical on Sept. 21. RA Capital purchased 1,300,000 shares of 89bio through a Sept. 17 offering that priced them at $28 apiece. RA Capital’s fresh investment lifted its stake in 89bio to 4,736,214 shares, equal to 23.8% of the outstanding stock.